Acute Respiratory Distress Syndrome
Conditions
Keywords
acute respiratory distress syndrome, microbiota, intensive care unit
Brief summary
Acute respiratory distress syndrome (ARDS) is due to diffuse and severe lung inflammation. Despite intensive research, few therapeutics have emerged and treatment is still mostly symptomatic. As lung microbiota seems to be associated with lung inflammation in numerous chronic respiratory diseases, this study aims to analyse the correlation between lung microbiota and mortality.
Detailed description
ARDS is caused by diffuse intense lun inflammation. Its mortality rate is still about 40%. Despite decades of research, few therapeutics have emerged. Treatment is based on the treatment of ARDS cause, if possible and on protective ventilation, curare use and prone position. For more severe cases, nitric monoxide inhalation and extra-corporeal membrane oxygenation can be considered. Nevertheless, no treatment specifically addresses lung inflammation. Lung microbiota has been shown to be associated with lung inflammation in asthma, chronic obstructive disease and cystic fibrosis. Lung microbiota also plays a role in lung immunity. Regarding specifically ARDS, one study correlated lung microbiota with the occurrence of non-infectious ARDS in trauma patients. Thi study therefore aims to analyse the correlation between lung microbiota at admission to ICU for ARDS with mortality.
Interventions
OTHERtracheal aspirate during routine care
tracheal aspirate during routine care
Sponsors
University of Bordeaux
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient above 18 year-old admitted to intensive care unit * ARDS according to Berlin criteria * Needing oro-tracheal intubation for mechanical ventilation * Within the first 48 hours of ARDS evolution
Exclusion criteria
* Guardianship or curatorship * Prisoners * No health insurance * No legal representative
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| lung bacteriobiota and ICU mortality | at admission | Comparison of lung bacteriobiota alpha diversity between ARDS ICU survivors and non-survivors |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| lung mycobiota and 1-month mortality | microbiota : at admission, mortality: 1 month after inclusion | Comparison of lung mycobiota alpha diversity between ARDS 1-month survivors and non-survivors |
| lung bacteriobiota and ICU mortality | at admission | Analysis of lung bacteriobiota beta diversity between ARDS ICU survivors and non-survivors |
| lung bacteriobiota and 1-month mortality | microbiota : at admission, mortality: 1 month after inclusion | Analysis of lung bacteriobiota beta diversity between ARDS 1-month survivors and non-survivors |
| lung mycobiota and ICU mortality | at admission | Comparison of lung mycobiota alpha diversity between ARDS ICU survivors and non-survivors |
| bacteria and 1-month mortality | microbiota : at admission, mortality: 1 month after inclusion | Association of bacteria with ARDS 1-month mortality by LefSe method |
| fungi and ICU mortality | at admission | Association of fungi with ARDS ICU mortality by LefSe method |
| fungi and 1-month mortality | microbiota : at admission, mortality: 1 month after inclusion | Association of fungi with ARDS 1-month mortality by LefSe method |
| bacteria and ICU mortality | at admission | Association of bacteria with ARDS ICU mortality by LefSe method |
Countries
France
Outcome results
None listed